630 5TH AVENUE, NEW YORK, NY
Other Events
Receives Expected Nasdaq Delinquency Notification
Departure of COO Felix Lauscher Amid Reorganization at Anavex Life Sciences
Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Appoints Seasoned Healthcare Leader to Board of Directors
Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Notice of Late Filing for Quarterly Report
Q1
FY 2024
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
S-3ASR
Preliminary Proxy Statement
Definitive Proxy Statement
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement